The H1-3 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical adenocarcinoma cell line, designed to disrupt expression of the H1-3 gene encoding histone H1.3. This polyclonal pool comprises a heterogeneous mixture of edited cells, providing a robust model for studying the collective impact of H1-3 loss on chromatin dynamics and cellular function without clonal selection bias. The product serves as a versatile tool for investigating linker histone biology in an epithelial cancer context.
The parental HeLa cell line is a widely used human epithelial cancer model, originally established in 1951 from a cervical adenocarcinoma of a 31-year-old Black woman. These adherent cells exhibit robust proliferation and have contributed extensively to biomedical research, including cancer biology, virology, and drug development. Their well-characterized genetic and epigenetic landscape makes them an ideal host for targeted gene disruption, enabling direct comparison of edited and wild-type populations in a controlled genetic background.
Histone H1.3 is a linker histone that binds nucleosomal DNA at the entry/exit sites of the nucleosome core particle, facilitating higher-order chromatin compaction and regulating access of transcriptional machinery. H1-3 activity is modulated by upstream regulators such as E2F transcription factors, NF-Y, CDK2, and cyclin E, and it interacts with key chromatin-associated proteins including HP1??, DNMT1, and PARP1. Disruption of H1-3 leads to looser chromatin architecture and altered nucleosome spacing, which in turn affects the expression of downstream targets like cyclin A2, cyclin B1, and pro-apoptotic genes, as well as the recruitment of chromatin remodeling complexes such as SWI/SNF and ISWI.
In the HeLa cervical adenocarcinoma background, H1-3 knockout likely perturbs the finely tuned chromatin organization that underlies cancerous gene expression programs. The resulting changes in chromatin accessibility and nucleosome positioning can directly impact cell cycle progression and DNA damage response pathways, both of which are frequently dysregulated in cervical cancer. Thus, this polyclonal knockout model provides a physiologically relevant system for dissecting how H1-3-mediated chromatin compaction contributes to oncogenic phenotypes and therapeutic vulnerabilities.
Researchers can employ this polyclonal H1-3 knockout cell population in a wide array of experimental workflows. Chromatin accessibility changes can be profiled by ATAC-seq, while micrococcal nuclease digestion assays reveal altered nucleosome positioning. Immunofluorescence and western blotting enable assessment of histone modifications and protein interactions, and RT-qPCR or flow cytometry can quantify downstream gene expression and cell cycle effects. These cells are particularly suited for studies of cancer epigenetics, chromatin structure-function relationships, and drug target discovery. For further technical details or custom inquiries, please contact Ascent Research.
